lung cancer Archives
Novel lung cancer biomarker
Jan. 9, 2023—Autoantibodies against the p53 tumor suppressor protein may be a novel biomarker for identifying people, especially African Americans, at high risk for lung cancer.
Lovly receives Asclepios Award from GO2 for Lung Cancer
Dec. 8, 2022—Vanderbilt's Christine Lovly, MD, PhD, has received the 2022 Asclepios Award, which recognizes lung cancer research pioneers.
Event set to make lung cancer screening more accessible
Oct. 20, 2022—Vanderbilt University Medical Center is making the lung cancer screening more convenient with weekend appointments from 8 a.m. to noon on Saturday, Nov. 12, at Vanderbilt Health One Hundred Oaks
Policy, resources crucial for lung cancer screening: study
Sep. 29, 2022—Vanderbilt reseach shows that resources for lung cancer screening programs increased the number of veterans screened.
Lung cancer detection program lands grant renewal
Sep. 15, 2022—The National Cancer Institute has renewed funding for the Early Detection Research Network Lung Cancer Clinical Validation Center at Vanderbilt- Ingram Cancer Center.
Targeted cancer drug during pregnancy
Aug. 2, 2022—The targeted cancer therapy alectinib was safe as a treatment for lung cancer during two pregnancies in a patient with non-small cell lung cancer, according to a case report from Vanderbilt physicians.
H. pylori and lung cancer
Aug. 1, 2022—Specific biomarkers for H. pylori — a bacterium that infects the stomach — were associated with increased risk of lung cancer, Vanderbilt researchers have discovered.
Study reveals need for matching targeted therapies with EGFR subtypes
Jul. 28, 2022—A Vanderbilt study suggests that clinicians should take a deeper dive into distinguishing EGFR mutations when prescribing targeted therapies for non-small-cell lung cancers.
VICC Scientific Retreat focuses on lung cancer
May. 5, 2022—by Tom Wilemon Speakers at the Vanderbilt-Ingram Cancer Center (VICC) 23rd Annual Scientific Retreat celebrated “Advances in Lung Cancer Research” but noted that too many people with the disease are not benefiting from those achievements. “Lung cancer is our leading cause of cancer mortality. Twenty-nine percent of our total cancers are lung cancer. That’s the...
Molecular testing across tumor types
Apr. 25, 2022—The KRAS inhibitor sotorasib is newly approved for one kind of lung cancer; Vanderbilt researchers ask if it should be considered for another type if the tumor has the gene mutation it targets.
AI used to identify patients at risk for lung cancer
Dec. 16, 2021— by Matt Batcheldor The Vanderbilt Lung Institute is the first location in Tennessee to debut Optellum Virtual Lung Nodule Clinic comprehensive management software that, using artificial intelligence, can identify and track patients at risk for lung cancer — even if they have never been in for a cancer screening. That’s because the Optellum software...
Clinical trial tests ATR inhibitor in difficult-to-treat cancers
Sep. 23, 2021— by Tom Wilemon A clinical trial has been launched to test a new targeted therapy in patients with advanced and difficult-to-treat cancers. Satya Das, MD, MSCI, assistant professor of Medicine at Vanderbilt-Ingram Cancer Center (VICC), is the national principal investigator for the trial (NCT04514497) that is now enrolling people with metastatic small cell lung...